Yeager 2005.

Study characteristics
Methods	Prospective, randomised, double‐blind, placebo‐controlled trial Run‐in period: recruitment over a period for 16 months (dates not specified). Published 2005 Number of study centres and location: not specified. Authors from Dartmouth Medical School, Hanover and Dartmouth‐Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Participants	Sixty elective cardiac surgical patients scheduled for CABG, cardiac valve replacement, or both Exclusion criteria: history of ongoing systemic inflammatory disease of any kind; treatment with systemic glucocorticoids for any reason within 3 months before admission.
Interventions	Intervention: etomidate and hydrocortisone (8 μg/kg over 6 h) Control: thiopentone and saline placebo
Outcomes	IL‐6, IL‐10, cortisol, MIF
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random sequence generation procedures were not clearly described.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not clearly described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not clearly described
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Authors state that the trial was double‐blinded, but they do not clearly describe how this was achieved.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No trial group changes, no withdrawals, and no losses to follow‐up were reported, but no intention‐to‐treat analysis. Data from all the participants were included in the final analysis.
Selective reporting (reporting bias)	Low risk	All outcomes were reported properly.
Other bias	Low risk	Quote: "Supported by grant NIAID AI051547 from the National Institutes of Health (PMG)" Funding source at low risk of bias